Citations

Clear

513 citation(s) found for "Ta, Casey".

Abstract PR05: A meta-analysis of genome-wide association study and eQTL analysis of multiple myeloma among African Americans
Du, Zhaohui , Weinhold, Niels , Song, Gregory, Rand, K.A., Hwang, Amie E. , Sheng, Xin , Hom, Victor, Pawlish, Karen , Peters, Edward , Mohrbacher, Ann, Stram, Alexander , Berndt, Sonja I. , Blot, William J. , Stevens, Victoria L. , Goodman, Phyllis J. , Hennis, Anselm , Nemesure, Barbara , Stanford, Janet L. , Witte, John S. , Signorello, Lisa B., John, Esther M. , Stroup, Antoinette M. , Zangari, Maurizio , Zheng, Wei , Hu, Jennifer J. , Carpten, John D. , Mehta, Jayesh, Wolf, Jeffrey L. , Martin, Thomas G. , Terebelo, Howard R. , Janakiraman, Nalini, Kolonel, Laurence N. , Auclair, Daniel , Vij, Ravi , Bernal‐Mizrachi, Leon , Zonder, Jeffrey A. , Huff, Carol Ann , Conti, David V. , Haiman, Christopher A. , John, Esther M , Zheng, Wei , Conti, David V , Berg, David Van Den , Ailawadhi, Sikander , Nooka, Ajay K. , Singhal, Seema , Bock, Cathryn Hufford , Stram, Alex , Casey, Graham , Kittles, Rick A. , Diver, W. Ryan , Klein, Eric A. , Rybicki, Benjamin A. , Bernstein, Leslie , Stephens, Owen , Rhee, Frits van , Olshan, Andrew F. , Ziegler, Regina G. , Nyante, Sarah J. , Ingles, Sue A. , Press, Michael F. , Chanock, Stephen Jacob , Colditz, Graham A. , Tomasson, Michael H. , Fiala, Mark A. , Anderson, Kenneth C. , Marchand, Loı̈c Le , Chiu, Brian C.‐H. , Ziv, Elad , Stram, Daniel O. , Morgan, Gareth J. , Lonial, Sagar , Orlowski, Robert Z. , Cozen, Wendy

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 1, 2020 | Volume: 29 | Issue: 6_Supplement_2 | Pages: PR05-PR05

10.1158/1538-7755.disp19-pr05 Get It

Abstract Background: Persons of African ancestry (AA) experience a 1.5-2-fold risk of multiple myeloma (MM) compared to persons of European ancestry (EA). We assembled a set of MM patients with self-reported AA in order to evaluate the contribution of genetics to etiology in this high-risk group. Methods: Here we present the results of a meta-analysis of two GWAS in 1,813 cases and 8,871 controls of AA. We also conducted an admixture mapping scan to identify risk alleles associated with local ancestry, fine-mapped the 23 known susceptibility loci to find markers that could better capture MM risk in individuals of AA, and constructed a polygenic risk score (PRS) to assess the aggregated effect of known MM risk alleles. Finally, we conducted an eQTL analysis measuring gene expression in those genes harboring a risk variant in malignant plasma cells from 292 of the patients from a single site. Results: In GWAS analysis, we identified two suggestive novel loci located at 9p24.3 and 9p13.1 at P<1 × 10-6, but no genome-wide significant association was noted. In admixture mapping, we observed a genome-wide significant inverse association between local AA at 2p24.1-23.1 and MM risk in AA individuals. 20 of the 23 known EA risk variants showed directional consistency and 9 replicated at P<0.05 in AA individuals. In eight regions, we identified markers that better capture MM risk in persons of AA. AA individuals with a PRS in the top 10% had a 1.82-fold (95%CI: 1.56, 2.11) increased MM risk compared to those with average risk (25-75%). The strongest functional association was between the risk allele for variant rs56219066 at 5q15 and lower ELL2 expression (P= 5.1 × 10–12). Conclusion: Our study shows that common genetic variation contributes to MM risk individuals of AA. This abstract is also being presented as Poster C040. Citation Format: Zhaohui Du, Niels Weinhold, Gregory Chi Song, Kristen A. Rand, David J. Van Den Berg, Amie E. Hwang, Xin Sheng, Victor Hom, Sikander Ailawadhi, Ajay K. Nooka, Seema Singhal, Karen Pawlish, Edward Peters, Cathryn Bock, Ann Mohrbacher, Alexander Stram, Sonja I. Berndt, William J. Blot, Graham Casey, Victoria L. Stevens, Rick Kittles, Phyllis J. Goodman, W. Ryan Diver, Anselm Hennis, Barbara Nemesure, Eric A. Klein, Benjamin A. Rybicki, Janet L. Stanford, John S. Witte, Lisa Signorello, Esther M. John, Leslie Bernstein, Antoinette Stroup, Owen W. Stephens, Maurizio Zangari, Frits Van Rhee, Andrew Olshan, Wei Zheng, Jennifer J. Hu, Regina Ziegler, Sarah J. Nyante, Sue Ann Ingles, Michael Press, John David Carpten, Stephen Chanock, Jayesh Mehta, Graham A Colditz, Jeffrey Wolf, Thomas G. Martin, Michael Tomasson, Mark A. Fiala, Howard Terebelo, Nalini Janakiraman, Laurence Kolonel, Kenneth C. Anderson, Loic Le Marchand, Daniel Auclair, Brian C.-H. Chiu, Elad Ziv, Daniel Stram, Ravi Vij, Leon Bernal-Mizrachi, Gareth J. Morgan, Jeffrey A. Zonder, Carol Ann Huff, Sagar Lonial, Robert Z. Orlowski, David V. Conti, Christopher A. Haiman, Wendy Cozen. A meta-analysis of genome-wide association study and eQTL analysis of multiple myeloma among African Americans [abstract]. In: Proceedings of the Twelfth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2019 Sep 20-23; San Francisco, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2020;29(6 Suppl_2):Abstract nr PR05.
Long-Term Follow-up of Hypophosphatemic Bone Disease Associated With Elemental Formula Use: Sustained Correction of Bone Disease After Formula Change or Phosphate Supplementation
Eswarakumar, Abigail S. , Nina, S. , Ward, Leanne M. , Wasserman, Halley , DiMeglio, Linda A. , Gagné, Julie, Cody, Declan, Zimakas, Paul, Topor, Lisa Swartz , Agrawal, Sungeeta , Calabria, Andrew C. , Tebben, Peter J. , Faircloth, Ruth, Gordon, Rebecca J. , Casey, Linda , Tebben, Peter, Carpenter, Thomas O , DiMeglio, Linda , Tebben, Peter , Backeljauw, Philippe Ferdinand , Weber, David R. , Imel, Erik Allen

Mayo Clinic

Clinical Pediatrics | July 15, 2020 | Volume: 59 | Issue: 12 | Pages: 1080-1085

10.1177/0009922820941097 | PMID 32666808 Get It

In this article, we describe the long-term outcomes of children who were previously reported to have developed hypophosphatemic bone disease in association with elemental formula use. An extended chart review allowed for an updated report of 34 children with regard to severity/duration of bone disease, extent of recovery, and time to correction using radiology reports and biochemical data. After implementation of formula change and/or phosphate supplementation, we found that serum phosphorus concentration increased and serum alkaline phosphatase activity decreased in all patients, normalizing by 6.6 ± 4.0 (mean ± SD) months following diagnosis. The decrease in serum alkaline phosphatase from diagnosis to the time of correction was moderately correlated with the concurrent increase in serum phosphorus ( R = 0.48, P < .05). Age at diagnosis significantly correlated with time to resolution ( R = 0.51, P = .01). This study supports the earlier report that bone disease associated with hypophosphatemia during elemental formula use responds to formula change and/or phosphate supplementation.
Exploratory Genome-Wide Interaction Analysis of Nonsteroidal Anti-inflammatory Drugs and Predicted Gene Expression on Colorectal Cancer Risk
Petersen, Paneen S., Schmit, Stephanie L. , Drew, David A. , Berndt, Sonja I. , Brenner, Hermann , Casey, Graham , Chang‐Claude, Jenny , Gallinger, Steven , Gruber, Stephen B. , Haile, Robert W. , Harrison, Tabitha A. , Hoffmeister, Michael , Jacobs, Eric J. , Joshi, Amit D. , Li, Li , Lindor, Noralane M. , Martín, Vicente , Maclnnis, Robert J., Moreno, Vı́ctor , Nan, Hongmei , Rennert, Gad , Slattery, Martha L. , Thibodeau, S. N., Weinstein, Stephanie J. , Woods, Michael O. , Peters, Ulrike , Brenner, Hermann , Rennert, Gad , Drew, David A , Brenner, Hermann , Gruber, Stephen B , Haile, Robert W , Harrison, Tabitha A , Hoffmeister, Michael , Martín, Vicente , Milne, Roger L , Maclnnis, Robert , Moreno, Victor , Potter, John D , Rennert, Gad , Slattery, Martha L , Thibodeau, Steve N, Weinstein, Stephanie J , Rennert, Gad , Brenner, Hermann , Nan, Hongmei , Wang, Xiaoliang , Su, Yu-Ru , Bien, Stephanie A. , Albanes, Demetrius , Campbell, Peter T. , Jenkins, Mark A. , Lin, Yi , Marchand, Loı̈c Le , Milne, Roger L. , Newcomb, Polly A. , Potter, John D. , Chan, Andrew T. , White, Emily , Hsu, Li

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | July 10, 2020 | Volume: 29 | Issue: 9 | Pages: 1800-1808

10.1158/1055-9965.epi-19-1018 | PMID 32651213 Get It

Abstract Background: Regular use of nonsteroidal anti-inflammatory drugs (NSAID) is associated with lower risk of colorectal cancer. Genome-wide interaction analysis on single variants (G × E) has identified several SNPs that may interact with NSAIDs to confer colorectal cancer risk, but variations in gene expression levels may also modify the effect of NSAID use. Therefore, we tested interactions between NSAID use and predicted gene expression levels in relation to colorectal cancer risk. Methods: Genetically predicted gene expressions were tested for interaction with NSAID use on colorectal cancer risk among 19,258 colorectal cancer cases and 18,597 controls from 21 observational studies. A Mixed Score Test for Interactions (MiSTi) approach was used to jointly assess G × E effects which are modeled via fixed interaction effects of the weighted burden within each gene set (burden) and residual G × E effects (variance). A false discovery rate (FDR) at 0.2 was applied to correct for multiple testing. Results: Among the 4,840 genes tested, genetically predicted expression levels of four genes modified the effect of any NSAID use on colorectal cancer risk, including DPP10 (PG×E = 1.96 × 10−4), KRT16 (PG×E = 2.3 × 10−4), CD14 (PG×E = 9.38 × 10−4), and CYP27A1 (PG×E = 1.44 × 10−3). There was a significant interaction between expression level of RP11-89N17 and regular use of aspirin only on colorectal cancer risk (PG×E = 3.23 × 10−5). No interactions were observed between predicted gene expression and nonaspirin NSAID use at FDR &lt; 0.2. Conclusions: By incorporating functional information, we discovered several novel genes that interacted with NSAID use. Impact: These findings provide preliminary support that could help understand the chemopreventive mechanisms of NSAIDs on colorectal cancer.
Single-nucleotide polymorphism biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancer
Barman, Poulami , Shepherd, Lois E. , Goss, Paul E. , Buzdar, Aman U. , Cairns, Junmei , Casey, Abraham Eyman, Goodnature, Barbara, Haddad, Tufia C. , Weinshilboum, Richard M. , Wang, Liewei , Eyman Casey, Abraham, Hoskin, Tanya L. , Goodnature, Barbara A, Ingle, James N. , Kalari, Krishna R. , Ellis, Matthew J. , Robson, Mark E. , Carlson, Erin E. , Goetz, Matthew P. , Weinshilboum, Richard M.

Mayo Clinic

Pharmacogenetics and Genomics | July 9, 2020 | Volume: 31 | Issue: 1 | Pages: 1-9

10.1097/fpc.0000000000000415 | PMID 32649577 Get It

Objectives Based on our previous findings that postmenopausal women with estrone (E1) and estradiol (E2) concentrations at or above 1.3 pg/ml and 0.5 pg/ml, respectively, after 6 months of adjuvant anastrozole therapy had a three-fold risk of recurrence, we aimed to identify a single-nucleotide polymorphism (SNP)-based model that would predict elevated E1 and E2 and then validate it in an independent dataset. Patients and methods The test set consisted of 322 women from the M3 study and the validation set consisted of 152 patients from MA.27. All patients were treated with adjuvant anastrozole, had on-anastrozole E1 and E2 concentrations and genome-wide genotyping. Results SNPs were identified from the M3 genome-wide association study. The best model to predict the E1-E2 phenotype with high balanced accuracy was a support vector machine model using clinical factors plus 46 SNPs. We did not have an independent cohort that is similar to the M3 study with clinical, E1-E2 phenotypes and genotype data to test our model. Hence, we chose a nested matched case-control cohort (MA.27 study) for testing. Our E1-E2 model was not validated but we found the MA.27 validation cohort was both clinically and genomically different. Conclusions We identified a SNP-based model that had excellent performance characteristics for predicting the phenotype of elevated E1 and E2 in women treated with anastrozole. This model was not validated in an independent dataset but that dataset was clinically and genomically substantially different. The model will need validation in a prospective study.
Cardiopulmonary Considerations for High School Student-Athletes During the COVID-19 Pandemic: NFHS-AMSSM Guidance Statement
Heinz, William M., Asif, Irfan M. , Batten, Casey G., Fields, Karl B., Valentine, Verle, Walter, Kevin D., Raukar, Neha P. , Drezner, Jonathan A. , Batten, Casey G.

Mayo Clinic

Sports Health: A Multidisciplinary Approach | July 9, 2020 | Volume: 12 | Issue: 5 | Pages: 459-461

10.1177/1941738120941490 | PMID 32640879 Get It

Trends in Medicare Reimbursement for Reconstructive Plastic Surgery Procedures: 2000 to 2019
Gupta, Nikita , Haglin, Jack M. , Marostica, Chance W., Thornburg, Danielle A. , Casey, William J.

Mayo Clinic

Plastic & Reconstructive Surgery | June 23, 2020 | Volume: 146 | Issue: 1 | Pages: 1541-1551

10.1097/prs.0000000000006914 | PMID 32590666 Get It

Background: An understanding of financial trends is important to advance agreeable reimbursement models in plastic surgery. This study aimed to evaluate trends in Medicare reimbursement rates for the 20 most commonly billed reconstructive plastic surgery procedures from 2000 to 2019. Methods: The Centers for Medicare and Medicaid Services Physician and Other Supplier Public Use File was used to identify the 20 reconstructive procedures most commonly billed to Medicare by plastic surgeons in 2016. Reimbursement data were extracted from The Physician Fee Schedule Look-Up Tool from the Centers for Medicare and Medicaid Services for each CPT code. Monetary data were adjusted for inflation to 2019 U.S. dollars. Average annual and total percentage changes in reimbursement were calculated based on these adjusted trends. Results: The average adjusted reimbursement for all procedures decreased by 14.0 percent from 2000 to 2019. The greatest mean decrease was observed in complex wound repair of the scalp, arms, or legs (−33.2 percent). The only procedure with an increased adjusted reimbursement rate was layer-closure of the scalp, axillae, trunk, and/or extremities (6.5 percent). From 2000 to 2019, the adjusted reimbursement rate for all procedures decreased by an average of 0.8 percent annually. Conclusions: This is the first comprehensive study evaluating trends in Medicare reimbursement in plastic surgery. When adjusted for inflation, Medicare reimbursement for the included procedures has steadily decreased from 2000 to 2019. Increased consideration of these trends will be important for U.S. policymakers, hospitals, and surgeons to ensure continued access to meaningful reconstructive plastic surgery care.
Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE)
Talhouk, Aline , Wang, Chen , Budden, Timothy , Kommoss, Stefan , Leong, Huei San, Intermaggio, Maria P., Nazeran, Tayyebeh M., Volchek, Mila, Elatre, Wafaa, Chow, Veronica, Sudderuddin, Hanwei , Mackenzie, Robertson, Leong, Samuel C.Y., Liu, Geyi, Johnson, Dustin, Chen, Billy, Group, AOCS, Alsop, Jennifer , Banerjee, Susana , Bodelón, Clara , Brand, Alison H. , Brinton, Louise A. , Carney, Michael E. , Chiew, Yoke-Eng , Cushing‐Haugen, Kara L. , Ennis, Darren , Fereday, Sián , Fortner, Renée T. , Greene, Casey S. , Hendley, Joy , Hernandez, Brenda Y. , Herpel, Esther , Jimenez‐Liñan, Mercedes , Karpinskyj, Chloe , Keeney, Gary L., Kennedy, Catherine J. , Köbel, Martin , Koziak, Jennifer M. , Lester, Jenny , Lewsley, Liz-Anne , Lissowska, Jolanta , Luk, Hugh, Mahner, Sven� , McNeish, Iain A. , Menkiszak, Janusz , Nevins, Nikilyn, Osório, Ana , Oszurek, Oleg, Pearce, Celeste Leigh , Pike, Malcolm C. , Piskorz, Anna , Rhenius, Valerie , Rodríguez‐Antona, Cristina , Sharma, Raghwa , Silva, Dilrini De , Singh, Naveena , Sinn, Hans‐Peter , Slamon, Dennis J. , Song, Honglin , Steed, Helen , Stronach, Euan A. , Thompson, Pamela J., Tołoczko, Aleksandra, Trabert, Britton , Traficante, Nadia , Tseng, Chiu-Chen , Widschwendter, Martin , Winterhoff, Boris , Beeghly‐Fadiel, Alicia, Brown, Robert , Chang‐Claude, Jenny , Chenevix‐Trench, Georgia , DeFazio, Anna , Fasching, Peter A. , García, María J. , Gayther, Simon A. , Goodman, Marc T. , Henderson, Michelle J. , Kelemen, Linda E. , Menon, Usha , Oršulić, Sandra , Wentzensen, Nicolas , Wu, Anna H. , Schildkraut, Joellen M. , Rossing, Mary Anne, Konecny, Gottfried E. , Huntsman, David G. , Huang, Ruby Yun‐Ju , Goode, Ellen L. , Ramus, Susan J. , Bowtell, David D.L. , Anglesio, Michael S. , George, Joshy , Wang, Chen , Tan, Tuan Zea , Behrens, Sabine , Bodelon, Clara , Brinton, Louise A , Fortner, Renée T , García-Donas, Jesús , Gentry‐Maharaj, Aleksandra , Glasspool, Rosalind , Greene, Casey S , Haluska, Paul , Harris, Holly R , Kaufmann, Scott H , Kennedy, Catherine J , Köbel, Martin , Koziak, Jennifer M , Lissowska, Jolanta , McNeish, Iain A , Menkiszak, Janusz , Hinsley, Samantha , Pike, Malcolm C , Rodríguez-Antona, Cristina , Sinn, Peter , Trabert, B , Widschwendter, Martin , Winham, Stacey J , Brenton, James D , Brown, Robert , Chang-Claude, Jenny , Fazio, Anna de , Fasching, Peter A , Kelemen, Linda E , Menon, Usha , Pharoah, Paul D P , Ramus, Susan J , Doherty, Jennifer A , Anglesio, Michael S , Chenevix-Trench, Georgia , Brand, Alison H , Ennis, Darren P , Traficante, Nadia , Bowtell, David D , Fereday, Sian , Hernandez, Brenda Y , Steed, Helen , Goodman, Marc T , Nevins, Nikilyn , George, Joshy , Chiu, Derek S , Chen, Stephanie , Gilks, C. Blake , Bentley, Rex C. , Senz, Janine , Lum, Amy M. , Group, AOCS, Behrens, Sabine , Cybulski, Cezary , García-Donás, Jesús , Glasspool, Rosalind , Goranova, Teodora , Harris, Holly R. , Kaufmann, Scott H. , Larson, Melissa C. , Lubiński, Jan , Macintyre, Geoff , Palacios, José , Ray-Coquard, Isabelle L. , Sherman, Mark E. , Wilkens, Lynne R. , Winham, Stacey J. , Beeghly‐Fadiel, Alicia , Benı́tez, Javier , Berchuck, Andrew , Brenton, James D. , Gronwald, Jacek , Karlan, Beth Y. , Pharoah, Paul D.P. , Doherty, Jennifer A.

Mayo Clinic

Clinical Cancer Research | June 17, 2020 | Volume: 26 | Issue: 20 | Pages: 5411-5423

10.1158/1078-0432.ccr-20-0103 | PMID 32554541 Get It

Abstract Purpose: Gene expression–based molecular subtypes of high-grade serous tubo-ovarian cancer (HGSOC), demonstrated across multiple studies, may provide improved stratification for molecularly targeted trials. However, evaluation of clinical utility has been hindered by nonstandardized methods, which are not applicable in a clinical setting. We sought to generate a clinical grade minimal gene set assay for classification of individual tumor specimens into HGSOC subtypes and confirm previously reported subtype-associated features. Experimental Design: Adopting two independent approaches, we derived and internally validated algorithms for subtype prediction using published gene expression data from 1,650 tumors. We applied resulting models to NanoString data on 3,829 HGSOCs from the Ovarian Tumor Tissue Analysis consortium. We further developed, confirmed, and validated a reduced, minimal gene set predictor, with methods suitable for a single-patient setting. Results: Gene expression data were used to derive the predictor of high-grade serous ovarian carcinoma molecular subtype (PrOTYPE) assay. We established a de facto standard as a consensus of two parallel approaches. PrOTYPE subtypes are significantly associated with age, stage, residual disease, tumor-infiltrating lymphocytes, and outcome. The locked-down clinical grade PrOTYPE test includes a model with 55 genes that predicted gene expression subtype with &gt;95% accuracy that was maintained in all analytic and biological validations. Conclusions: We validated the PrOTYPE assay following the Institute of Medicine guidelines for the development of omics-based tests. This fully defined and locked-down clinical grade assay will enable trial design with molecular subtype stratification and allow for objective assessment of the predictive value of HGSOC molecular subtypes in precision medicine applications. See related commentary by McMullen et al., p. 5271
Implementing High-Sensitivity Cardiac Troponin T in a US Regional Healthcare System
Sandoval, Yader , Askew, J. Wells , Newman, James S. , Clements, Casey M. , Grube, Eric D., Ola, Olatunde , Akula, Ashok , Dworak, Marshall , Wohlrab, Scott, Karon, Brad S. , Jaffe, Allan S. , Grube, Eric D., Jaffe, Allan S.

Mayo Clinic

Circulation | June 8, 2020 | Volume: 141 | Issue: 23 | Pages: 1937-1939

10.1161/circulationaha.119.045480 | PMID 32510995 Get It